Related Articles
Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review)
Long‑term complete response in a patient with postoperative recurrent ALK‑rearranged lung adenocarcinoma treated with crizotinib: A case report
EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer
Anaplastic lymphoma kinase‑positive squamous cell carcinoma of the lung: A case report
Crizotinib-associated toxic epidermal necrolysis in an ALK-positive advanced NSCLC patient